Forced degradation studies of biopharmaceuticals: Selection of stress conditions

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 98, Issue , 2016, Pages 26-46

  Tamizi, Elnaz ^a   Jouyban, Abolghasem ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biopharmaceutical; Forced degradation; Stability; Stress condition; Stress testing

Indexed keywords

BIOLOGICAL PRODUCT; BIOPHARMACEUTICAL AGENT; PIPERAZINEDIONE; UNCLASSIFIED DRUG; DISULFIDE; PROTEIN;

ANALYTIC METHOD; BIOLOGICAL ACTIVITY; CHEMICAL STRESS; DEAMINATION; DEGRADATION; DISULFIDE BOND; DISULFIDE BOND BREAKAGE; DRUG INDUSTRY; DRUG POTENCY; DRUG STABILITY; ENVIRONMENTAL FACTOR; EPIMERIZATION; GLYCATION; HYDROLYSIS; ISOMERIZATION; LIGHT EXPOSURE; OXIDATION; PH; PHYSICAL CHEMISTRY; PRECIPITATION; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DENATURATION; PROTEIN STRUCTURE; PROTEIN UNFOLDING; RACEMIZATION; REVIEW; TEMPERATURE STRESS; CHEMISTRY; MECHANICAL STRESS; MEDICINAL CHEMISTRY; OXIDATION REDUCTION REACTION; PHARMACEUTICS; PROTEIN FOLDING;

BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; DISULFIDES; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; OXIDATION-REDUCTION; PROTEIN FOLDING; PROTEINS; STRESS, MECHANICAL;

EID: 84946866374     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.10.016     Document Type: Review

References (136)

1. G. Zhang Mammalian cell culture for biopharmaceutical production R.H. Baltz, J.E. Davies, A.L. Dermain, Manual of Industrial Microbiology and Biotechnology third ed. 2010 ASM Press Washington, DC 157
2. M.A. Alsenaidy, N.K. Jain, J.H. Kim, C.R. Middaugh, and D.B. Volkin Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles Front. Pharmacol. 5 2014 39
3. J.M. Reichert Antibodies to watch in 2015 MABs 7 2015 1 8
4. A.L. Daugherty, and R.J. Mrsny Formulation and delivery issues for monoclonal antibody therapeutics Adv. Drug Deliv. Rev. 58 2006 686 706
5. V. Filipe, A. Hawe, J.F. Carpenter, and W. Jiskoot Analytical approaches to assess the degradation of therapeutic proteins TRAC - Trends Anal. Chem. 49 2013 118 125
6. W. Wang Instability, stabilization and formulation of liquid protein pharmaceuticals Int. J. Pharm. 185 1999 129 188
7. J.L.E. Reubsaet, J.H. Beijnen, A. Bult, R.J. Maanen, J.A.D. Marchal, and W.J.M. Underberg Analytical techniques used to study the degradation of proteins and peptides: physical instability J. Pharm. Biomed. Anal. 17 1998 979 984
8. P. Arora, R. Gandhi, and T. Kelly Overview of Drug Development for Protein Therapeutics: Present Strategies and Future Perspectives 2011 American Pharmaceutical Review < http://www.kbibiopharma.com/assets/Overview-of-Drug-Product-Development-for-Protein-Therapeutics.pdf > (accessed September 2015)
9. J.M.A. Gavina, and P. Britz-McKibbin Protein unfolding and conformational studies by capillary electrophoresis Curr. Anal. Chem. 3 2007 17 31
10. ICH, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q5C: Stability Testing of Biotechnological/Biological Products, Geneva, 1995. < http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q5C/Step4/Q5C-Guideline.pdf > (accessed September 2015).
11. W. Wang Potency Testing of Biopharmaceuticals 2014 American Pharmaceutical Review, The Review of American Pharmaceutical Technology & Business < http://www.americanpharmaceuticalreview.com/Featured-Articles/169473-Potency-Testing-of-Biopharmaceutical-Products/ > (accessed September 2015)
12. K.B. Ajay Stability of therapeutic peptides and proteins A.K. Banga, Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems second ed. 2006 CRC Boca Raton 67 83
13. M.S. Hora, and B.L. Chen Stabilization of biopharmaceutical products and finish product formulations G. Walsh, B. Murphy, Biopharmaceuticals: An Industrial Perspective 1999 Kluwer Academic Publishers Dordrecht 218 225
14. M. Blessy, R.D. Patel, P.N. Prajapati, and Y.K. Agrawal Development of forced degradation and stability indicating studies of drugs - a review J. Pharm. Anal. 4 2014 159 165
15. M. Bakshi, and S. Singh Development of validated stability-indicating assay methods - critical review J. Pharm. Biomed. Anal. 28 2002 1011 1040
16. R.M. Maggio, S.E. Vignaduzzo, and T.S. Kaufman Practical and regulatory considerations for stability-indicating methods for the assay of bulk drugs and drug formulations TRAC - Trends Anal. Chem. 49 2013 57 70
17. S.R.J. Hicks Forced Degradation to Develop Stability-indicating Methods vol. 13 2012 Pharm. Outsourcing < http://www.pharmoutsourcing.com/Featured-Articles/37640-Forced-Degradation-to-Develop-Stability-indicating-Methods/ > (accessed September 2015)
18. ICH, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q1A (R2): Stability Testing of New Drug Substances and Products, 2003. < http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q1A-R2/Step4/Q1A-R2-Guideline.pdf > (accessed September 2015).
19. ICH, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q1B: Stability Testing: Photostability Testing of New Drug Substances and Products, 1996. < http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q1B/Step4/Q1B-Guideline.pdf > (accessed September 2015).
20. ASTM, The American Society for Testing Materials, Designation: D 999-01: Standard Test Methods for Vibration Testing of Shipping Containers, 2007.
21. M. Hashija, L. Li, N. Rahman, and S.F. Ausar Force degradation studies: an essential tool for the formulation and development of vaccines Vaccine 3 2013 11 33
22. A. Hawe, M. Wiggenhorn, M. van de Weert, J.H.O. Garbe, H.C. Mahler, and W. Jiskoot Force degradation of therapeutic proteins J. Pharm. Sci. 101 2012 895 913
23. A. Gervais, Concept Paper on Force Degradation Studies, CASSS CMC Strategy Forum - EBE Satellite Session - Sorrento - May 5, 2014. < http://c.ymcdn.com/sites/www.casss.org/resource/resmgr/CMC-Euro-Speaker-Slides/2014-CMCE-GervaisAnnick.pdf > (accessed September 2015).
24. T.N. Laremore, F. Zhang, J.S. Dordick, J. Liu, and R.J. Linhardt Recent progress and applications in glycosaminoglycan and heparin research Curr. Opin. Chem. Biol. 13 2009 633 640
25. R.A. Rader (Re)defining biopharmaceutical Nat. Biotechnol. 26 2008 743 751
26. R. Krishnamoorthy, and A.K. Mitra Kinetics and mechanism of degradation of a cyclic hexapeptide (somatostatin analogue) in aqueous solution Pharm. Res. 10 1992 1314 1320
27. S.W. Jang, B.H. Woo, J.T. Lee, S.C. Moon, K.C. Lee, and P.P. DeLuca Stability of octastatin, a somatostatin analog cyclic octapeptide, in aqueous solution Pharm. Dev. Technol. 2 1997 409 414
28. C. Oliyai, and R.T. Borchardt Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanisms of degradation of an aspartyl residue in a model hexapeptide Pharm. Res. 10 1993 95 102
29. M.A. Hoitink, J.H. Beijnen, M.U.S. Boschma, A. Bult, E. Hop, J. Nijholt, C. Versluis, G. Wiese, and W.J.M. Underberg Identification of the degradation products of gonadorelin and three analogues in aqueous solution Anal. Chem. 69 1997 4972 4978
30. Y. Nabuchi, E. Fujiwara, H. Kuboniwa, Y. Asoh, and H. Ushio The stability and degradation pathway of recombinant human parathyroid hormone: deamidation of asparaginyl residue and peptide bond cleavage at aspartyl and asparaginyl residues Pharm. Res. 14 1997 1685 1690
31. A.B. Joshi, E. Rus, and L.E. Kirsch The degradation pathways of glucagon in acidic solutions Int. J. Pharm. 203 2000 115 125
32. N. Caputo, J.R. Castle, C.P. Bergstorm, J.M. Carroll, P.A. Bakhtiani, M.A. Jackson, C.T. Roberts Jr., L.L. David, and W.K. Ward Mechanisms of glucagon degradation at alkaline pH Peptides 45 2013 40 47
33. A. Hawe, R. Poole, S. Romeijn, P. Kasper, R. van der Heijden, and W. Jiskoot Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products Pharm. Res. 26 2009 1679 1688
34. R. Haselberg, V. Brinks, A. Hawe, G.J. de Jong, and G.W. Somsen Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals Anal. Bioanal. Chem. 400 2011 295 303
35. F.C. Neale, J.S. Clubb, D. Hotchkis, and S. Posen Heat stability of human placental alkaline phosphatase J. Clin. Pathol. 18 1965 359 363
36. H.J.C. Eriksson, M. Wijngaard, W.L.J. Hinrichs, H.W. Frijlink, G.W. Somsen, and G.J. de Jong Potential of capillary electrophoresis for the monitoring of the stability of placental alkaline phosphatase J. Pharm. Biomed. Anal. 31 2003 351 357
37. Y. Nabuchi, E. Fujiwara, K. Ueno, H. Kuboniwa, Y. Asoh, and H. Ushio Oxidation of recombinant human parathyroid hormone: effect of oxidized position on the biological activity Pharm. Res. 12 1995 2049 2052
38. Interferon alfa-2a concentrated solution, monograph 1110, in: European Pharmacopoeia, fifth ed., Council of Europe, Strasbourg, France, 2005, pp. 1812-1815.
39. M.M.C.G. Silva, B. Lamarre, E. Cerasoli, P. Rakowska, A. Hills, M.J.A. Bailey, J.X. Wheeler, C.J. Burns, R.E. Gianes-Das, C. Jones, and C.J. Robinson Physicochemical and biological assays for quality control of biopharmaceuticals: interferon alfa-2 case study Biologicals 36 2008 383 392
40. P. Qi, D.B. Volkin, H. Zhao, M.L. Nedved, R. Hughes, R. Bass, S.C. Yi, M.E. Panek, D. Wang, P. Dalmonte, and M.D. Bond Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form J. Pharm. Sci. 98 2009 3117 3130
41. R. Rotival, M. Bernard, T. Henriet, M. Fourgeaud, J.R. Fabreguettes, E. Surget, f. Guyon, and B. Do Comprehensive determination of the cyclic FEE peptide chemical stability in solution J. Pharm. Biomed. Anal. 89 2014 50 55
42. M.C. Manning, D. Chou, B.M. Murphy, R.W. Payne, and D.S. Katayama Stability of protein pharmaceuticals: an update Pharm. Res. 27 2010 544 574
43. V. Timm, P. Gruber, M. Wasiliu, H. Lindhofer, and D. Chelius Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies J. Chromatogr. B 878 2010 777 784
44. T. Gieger, and S. Clarke Deamidation, isomerization and racemization at asparaginyl and aspartyl residues in peptides J. Biol. Chem. 262 1986 785 794
45. J. Sydow, F. Lipsmeier, V. Larraillet, M. Hilger, B. Mautz, M. Molhoj, J. Kuentzer, S. Klostermann, J. Schoch, H.R. Voelger, J.T. Regula, P. Cramer, A. Papadimitriou, and H. Kettenberger Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions PLoS ONE 9 2014 e100736
46. A.B. Joshi, and L.E. Kirsch The relative rate of glutamine and asparagine deamidation in glucagon fragment 22-29 under acidic conditions J. Pharm. Sci. 91 2002 2331 2345
47. A.B. Joshi, and L.E. Kirsch The estimation of glutaminyl deamidation and aspartyl cleavage rates in glucagon Int. J. Pharm. 273 2004 213 219
48. J.R. Catai, H.A. Tervahauta, G.J. de Jong, and G.W. Somsen Noncovalently bilayer-coated capillaries for efficient and reproducible analysis of proteins by capillary electrophoresis J. Chromatogr. A 1083 2005 185 192
49. J.S. Creamer, S.T. Krauss, and S.M. Lunte Capillary electrophoresis separation of desamino degradation products of oxytocin Electrophoresis 35 2014 563 569
50. J. Vlasak, M.C. Bussat, S. Wang, E. Wangner-Rousset, M. Schaefer, C. Klinguer-Hamour, N. Corvaïa, R. Ionescu, and A. Beck Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody Anal. Biochem. 392 2009 145 154
51. J.R. Catai, J.S. Torano, P.M.J.K. Jongen, G.J. de Jong, and G.W. Somsen Analysis of recombinant human growth hormone by capillary electrophoresis with bilayer-coated capillaries using UV and MS detection J. Chromatogr. B 852 2007 160 166
52. A. Taichrib, M. Pelzing, C. Pellegrino, M. Rossi, and C. Neusuß High resolution TOF-MS coupled to CE for the analysis of isotopically resolved intact proteins J. Proteom. 74 2011 958 966
53. K. Deipold, K. Bomans, M. Wiedmann, B. Zimmermann, A. Petzold, T. Schlothauer, R. Mueller, B. Moritz, J.O. Stracke, M. Mølhøj, D. Reusch, and P. Bulau Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures PLoS ONE 7 2012 e30295
54. R. Kothari, V. Kumar, R. Jena, R. Tunga, and B.S. Tunga Modes of degradation and impurity characterization in rhPTH (1-34) during stability studies PDA - J. Pharm. Sci. Technol. 65 2011 348 362
55. J.Y. Zheng, and L.J. Janis Influence of pH, buffer species and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298 Int. J. Pharm. 308 2006 46 51
56. J. Patel, R. Kothari, R. Tunga, N.M. Ritter, and B.S. Tunga Stability Considerations for Biopharmaceuticals, Part 1: Overview of Protein and Peptide Degradation Pathways 2011 Bioprocess Int. < http://www.bioprocessintl.com/manufacturing/formulation/stability-considerations-for-biopharmaceuticals-part-1-332821/ > (accessed September 2015)
57. S. Li, T.H. Nguyen, C. Schöneich, and R.T. Borchrdt Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation Biochemistry 34 1995 5762 5772
58. Y. Nabuchi, E. Fujiwara, H. Kuboniwa, Y. Asoh, and H. Ushio Kinetic study of methionine oxidation in human parathyroid hormone Anal. Chim. Acta 365 1998 301 307
59. C. Chumsae, G. Gaza-Bulseco, J. Sun, and H. Liu Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody J. Chromatogr. B 850 2007 285 294
60. G. Gaza-Bulseco, S. Faldu, K. Hurkmans, C. Chumsae, and H. Liu Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G J. Chromatogr. B 870 2008 55 62
61. H. Liu, G. Gaza-Bulseco, T. Xiang, and C. Chumsae Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody Mol. Immunol. 45 2008 701 708
62. H. Liu, G. Gaza-Bulseco, and L. Zhou Mass spectroscopy analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody J. Am. Soc. Mass Spectrom. 20 2009 525 528
63. M. Hensel, R. Steurer, J. Fichtl, C. Elger, F. Wedekind, A. Petzold, T. Schlothauer, M. Molhoj, D. Reusch, and P. Bulau Identification of potential sites for tryptophan oxidation in recombinant antibodies using tert-butylhydroperoxide and quantitative LC-MS PLoS ONE 6 2011 e17708
64. Y. Alahmad, N.T. Tran, I.L. Potier, E. Forest, S. Jorieux, and M. Taverna A new CZE method for profiling human serum albumin and its related forms to assess the quality of biopharmaceuticals Electrophoresis 32 2011 292 299
65. E. Pedroso, A. Grandas, X. de las Heras, R. Eritja, and E. Giralt Diketopiperazine formation in solid phase peptide synthesis using e-alkoxybenzyl ester resins and FMOC-amino acids Tetrahedron Lett. 27 1986 743 746
66. M.F. Powell A compendium and hydropathy/flexibility analysis of common reactive sites in proteins: reactivity of Asn, Asp, Gln and Met motifs in neutral pH solution R. Pearlman, Y.J. Wang, Formulation, Characterization, and Stability of Protein Drugs 1996 Plenum Press New York 7 8
67. C. Goolcharran, and R.T. Borchardt Kinetics of diketopiperazine formation using model peptides J. Pharm. Sci. 87 1998 283 288
68. M.A. Hoitink, J.H. Beijnen, M.U.S. Boschma, A. Bult, O.A.G.J. van der Houwen, G. Wiese, and W.J. Undreberg Degradation kinetics of three gonadorelin analogous: developing a method for calculating epimerization parameters Pharm. Res. 15 1998 1449 1455
69. J. Gysler, B. Helk, S. Dambacher, U.R. Tjaden, and J. van der Greef Characterization of recombinant cytokine fragments using isotachophoresis-capillary zone electrophoresis, reversed-phase high performance liquid chromatography, and mass spectrometry Pharm. Res. 16 1999 695 701
70. O. Salas-Solano, B. Tomlinson, S. Du, M. Parker, A. Strahan, and S. Ma Optimization and validation of a quantitative capillary electrophoresis sodium dodecyl sulfate method for quality control and stability monitoring of monoclonal antibodies Anal. Chem. 78 2006 6583 6594
71. D.J. Kroon, A. Baldwin-Ferro, and P. Lalan Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping Pharm. Res. 9 1992 1386 1393
72. K.F. Greve, D.E. Hughes, P. Richberg, M. Kats, and B.L. Karger Liquid chromatographic and capillary electrophoretic examination of intact and degraded fusion protein CTLA4Ig and kinetics of conformational transitions J. Chromatogr. A 723 1996 279 284
73. N. Ceaglio, M. Etcheverrigaray, R. Kratje, and M. Oggero Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein Biochimie 92 2010 971 978
74. U. Conrad, A. Fahr, and G.K.E. Scriba Kinetics of aspartic acid isomerization and enantiomerization in model aspartyl tripeptides under forced conditions J. Pharm. Sci. 99 2010 4162 4173
75. T. Wang, O.S. Kumru, L. Yi, J. Wang, J. Zhang, J.H. Kim, S.B. Joshi, C.R. Middaugh, and D.B. Volkin Effect of ionic strength and pH on the physical and chemical stability of monoclonal antibody antigen-binding fragment Pharm. Res. 102 2013 2520 2537
76. J. Yang, S. Wang, J. Liu, and A. Raghani Determination of tryptophan oxidation of monoclonal antibody by reversed phase high performance liquid chromatography J. Chromatogr. A 1156 2007 174 182
77. 2+ complex as stationary phase J. Sep. Sci. 32 2009 3930 3935
78. A. Diress, B. Lorbetskie, L. Larocque, X. Li, M. Alteen, R. Isbrucker, and M. Girard Study of aggregation, denaturation and reduction of interferon alph-2 products by size-exclusion high-performance liquid chromatography with fluorescence detection and biological assays J. Chromatogr. A 1217 2010 3297 3306
79. A. Vanhooren, B. Devreese, K. Vanhee, J. van Beeumen, and I. Hanssens Photoexcitation of tryptophan groups induces reduction of two disulfide bonds in goat α-lactalbumin Biochemistry 41 2002 11035 11043
80. B.L. Miller, M.J. Hageman, T.J. Thamann, L.B. Barrón, and C. Schöneich Solid-state photodegradation of bovine somatotropin (bovine growth hormone): evidence for tryptophan-mediated photooxidation of disulfide bonds J. Pharm. Sci. 92 2003 1698 1709
81. M. Paborji, N.L. Pochopin, W.P. Coppola, and J.B. Bogardus Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody Pharm. Res. 11 1994 764 771
82. R.R. Rustandi, M.W. Washabaugh, and Y. Wang Application of CE SDS gel in development of biopharmaceutical antibody-based products Electrophoresis 29 2008 3612 3620
83. A. Usami, A. Ohtsu, S. Takahama, and T. Fujji The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody Pharm. Biomed. Anal. 14 1996 1133 1140
84. S. Marquette, C. Peerboom, A. Yates, L. Denis, I. Langer, K. Amighi, and J. Goole Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheres Int. J. Pharm. 470 2014 41 50
85. M. Jaworska, G. Kłakzkow, M. Wilk, and E. Anuszewska Analysis of biologically active peptides using two-dimensional HPLC-CE Acta Pol. Pharm. - Drug Res. 69 2012 797 808
86. D.G. Lim, N.A. Kim, J.Y. Lim, K.H. Kim, S. Hada, and S.H. Jeong Evaluation of etanercept stability as exposed to various sugars with biophysical assessment Int. J. Pharm. 476 2014 50 59
87. K.A. Jandik, D. Kruep, M. Cartier, and R.J. Lindhardt Accelerated stability studies of heparin J. Pharm. Sci. 85 1996 45 51
88. A.J. Alexander, and D.E. Hughes Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry Anal. Chem. 67 1995 3626 3632
89. D. Houde, P. Kauppinen, R. Mhatre, and Y. Lyubarskaya Determination of protein oxidation by mass spectrometry and method transfer to quality control J. Chromatogr. A 1123 2006 189 198
90. B.R. Souto, F.P. Stamm, M.T.C.P. Ribela, P. Bartolini, G.Z. Calegari, and S.L. Dalmora Validation of a stability-indicating RP-LC method for the assessment of recombinant human interleukin-11 and its correlation with bioassay Anal. Sci. 28 2012 215 220
91. D.P. Leal, R.B. Souto, R. Schutkoski, A.C. Bergamo, and S.L. Dalmora Granulocyte-macrophage colony stimulating factor: evaluation of biopharmaceutical formulations by stability-indicating RP-LC method and bioassay Biologicals 39 2011 211 216
92. S.L. Dalmora, C.S. Butzge, F.T. Machado, M.E. Walter, M.E.A. Dalmora, and R.B. Souto Stability-indicating capillary zone electrophoresis method for the assessment of recombinant human granulocyte-macrophage colony-stimulating factor and its correlation with reversed-phase liquid chromatography method and bioassay Talanta 97 2012 1 7
93. E. Tamizi, E. Kenndler, and A. Jouyban A stability indicating capillary electrophoresis method for analysis of buserelin Iran. J. Pharm. Res. 13 2014 797 807
94. E. Tamizi, and A. Jouyban A simple stability indicating CZE method for analysis of octreotide acetate Chromatographia 77 2014 1347 1357
95. R.B. Souto, F.P. Stamm, J.B. Schumacher Jr., C.D.A. Cardoso, G.W. de Freitas, R.F. Perobelli, and S.L. Dalmora Stability-indicating capillary zone electrophoresis method for the assessment of recombinant human interleukin-11 and its correlation with reversed-phase liquid chromatography and bioassay Talanta 123 2014 179 185
96. R.P. Patel, C. Narkowicz, J.P. Hutchinson, E.F. Hilder, and G.A. Jacobson A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins J. Pharm. Biomed. Anal. 46 2008 30 35
97. E. Tamizi, and A. Jouyban Development and validation of a simple and rapid capillary zone electrophoresis method for quantification of heparin in a pharmaceutical product and stability studies Pharm. Anal. Acta 3 2012 170
98. S. Caserman, V. Menart, R.G. Das, S. Williams, and A. Meager Thermal stability of the WHO international standard of interferon alpha 2b (IFN-α2b): application of new reporter gen assay for IFN-α2b potency determinations J. Immunol. Methods 319 2007 6 12
99. P.T. Doung, L. Lloyd, Analysis of Oxidized Insulin Chains Using Reverse Phase Agilent ZORBAX RRHD 300SB-C18, Application Note from Agilent Technologies, 2011. < http://www.chem.agilent.com/Library/applications/5990-7988EN.pdf > (accessed September 2015).
100. S. Klapoetke, S. Zheng, S. Becht, X. Ding, Characterization of Impurities from a Force Degradation Study of Bovine Insulin Using LC/Q-TOF MS/MS. < http://druginfo.com/resource-library/posters/Characterization-of-Impurities-Poster.pdf > (accessed September 2015).
101. G. Benković, A. Škrlin, T. Madić, Ž. Debeljak, and M. Medić-Šarić Purity assessment of recombinant human granulocyte colony-stimulating factor in finished drug product by capillary zone electrophoresis Electrophoresis 35 2014 2608 2614
102. J. Rivers, L. McDonald, I.J. Edwards, and R.J. Beynon Asparagine deamidation and the role of higher order protein structure J. Proteome Res. 7 2008 921 927
103. C.L. Stevenson Effect of secondary structure on the rate of deamidation of several growth hormone releasing factor analogs Int. J. Pep. Prot. Res. 42 1993 497 503
104. S.L. Krogmeier, D.S. Reddy, D. Vander Velde, G.H. Lashington, T.G. Siahaan, C.R. Middaugh, R.T. Borchardt, and E.M. Topp Deamidation of model β-turn cyclic peptides in the solid state J. Pharm. Sci. 94 2005 2616 2631
105. B.S. Chang, and B. Bernice Yeung Physical stability of protein pharmaceuticals F. Jameel, S. Hershenson, Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals 2010 John Willy & Sons Inc. Hoboken 69 104
106. T. Arakawa, S.J. Prestrelski, W.C. Kenny, and J.F. Carpenter Factors affecting short-term and long-term stabilities of proteins Adv. Drug Deliv. Rev. 46 2001 307 326
107. K.A. Britt, D.K. Schwartz, C. Wurth, H.C. Mahler, J.F. Carpenter, and T.W. Randolph Excipient effects on humanized monoclonal antibody interactions with silicone oil emulsions J. Pharm. Sci. 101 2012 4419 4432
108. M.A. Miller, M.A. Rodrigues, M.A. Glass, S.K. Singh, K.P. Johnston, and J.A. Maynard Frozen-state storage stability of a monoclonal antibody: aggregation is impacted by freezing rate and solute distribution J. Pharm. Sci. 102 2013 1194 1208
109. N. Chennamsetty, V. Voynov, V. Kayser, B. Helk, and B.L. Trout Design of therapeutic proteins with enhanced stability Proc. Natl. Acad. Sci. U.S.A. 106 2009 11937 11942
110. C. Kalonia, O.S. Kumru, J.H. Kim, C.R. Middaugh, and D.B. Volkin Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques J. Pharm. Sci. 102 2013 4256 4267
111. A. Oliva, M. Llabrés, and J.B. Fariña Capability measurement of size-exclusion chromatography with a light-scattering detection method in a stability study of bevacizumab using the process capability indices J. Chromatogr. A 1353 2014 89 98
112. E. Longo, E. De Santis, R. Hussain, C.F. van der Walle, J. Casas-Finet, S. Uddin, A.D. Santos, and G. Siligardi The effect of palmitoylation on the conformation and physical stability of a model peptide hormone Int. J. Pharm. 472 2014 156 164
113. Y.M. Kim, H.J. Lee, J.E. Lee, H.Y. Kim, and J. Kim Expression of human interferon α-1 with enhanced stability via the tagging system of a stabilizing peptide Prot. Exp. Purif. 36 2009 140 146
114. A. van Maarschalkerweerd, G.-D. Wolbink, S.O. Stapel, W. Jiskoot, and A. Hawe Comparison of analytical methods to detect instability of etanercept during thermal stress testing Eur. J. Pharm. Biopharm. 78 2011 213 221
115. M. Gottschalk, K. Venu, and B. Halle Protein self-association in solution: the bovine pancreatic trypsin inhibitor decamer Biophys. J. 84 2003 3941 3958
116. J.L. Fast, A.A. Cordes, J.F. Carpenter, and T.W. Randolph Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability J. Pharm. Sci. 48 2009 11724 11736
117. A.A. Cordes, J.F. Carpenter, and T.W. Randolph Accelerated stability studies of abatacept formulations: comparison of freeze-thawing and agitation induced stresses J. Pharm. Sci. 11 2012 2307 2315
118. S.N. Telikepalli, O.S. Kumru, C. Kalonia, R. Esfandiary, S.B. Joshi, C.R. Middaugh, and D.B. Volkin Structural characterization of IgG1 mAb aggregates and particles created under various stress conditions J. Pharm. Sci. 103 2014 796 809
119. S.N. Telikepalli, O.S. Kumru, C. Kalonia, J.H. Kim, S.B. Joshi, K.B. Oberry, A.W. Blake-Haskins, M.D. Perkins, C.R. Middaugh, and D.B. Volkin Characterization of the physical stability of lyophilized IgG1 mAb after accelerated shipping-like stress J. Pharm. Sci. 104 2015 495 507
120. M. Kats, P.C. Richberg, and D.E. Hughes Conformational diversity and conformational transitions of a monoclonal antibody monitored by circular dichroism and capillary electrophoresis Anal. Chem. 67 1995 2943 2948
121. M. Kats, P.C. Richberg, and D.E. Hughes PH-dependent isoform transitions of a monoclonal antibody monitored by micellar electrokinetic capillary chromatography Anal. Chem. 69 1997 338 343
122. K.H. Strucksberg, T. Rosenkranz, and J. Fitter Reversible and irreversible unfolding of multi-domain proteins Biochim. Biophys. Acta 1774 2007 1591 1603
123. F. Zehender, A. Ziegler, H.-J. Schönfeld, and J. Seelig Thermodynamics of protein self-association and unfolding. The case of apolipoprotein A-I Biochemistry 15 2014 1269 1280
124. K.K. Biggar, N.J. Dawson, and K.B. Storey Real-time protein unfolding: a method for determining the kinetics of native protein denaturation using a quantitative real-time thermocycler Biotechniques 53 2012 231 238
125. J. Polanec, I. Seppälä, S. Rousseau, and K. Hedman Evaluation of protein-denaturing immunoassays for avidity of immunoglobulin G to rubella virus J. Clin. Lab. Anal. 8 1994 16 21
126. G. Hummer, S. Garde, A.E. García, M.E. Paulaitis, and L.R. Pratt The pressure dependence of hydrophobic interactions is consistent with the observed pressure denaturation of proteins Proc. Natl. Acad. Sci. U.S.A. 95 1998 1552 1555
127. A.V. Hernández-Moreno, F.C. Perdomo-Abúndez, V.P.-M. Martínez, G. Luna-Bárcenas, F. Villaseñor-Ortega, N.O. Pérez, C.A. López-Morales, L.F. Flores-Ortiz, and E. Medina-Rivero Structural and functional characterization of a recombinant leucine aminopeptidase J. Mol. Catal. B - Enzym. 113 2015 39 46
128. S. Zhang, K. Xia, W.K. Chung, S.M. Cramer, and W. Colon Identifying kinetically stable proteins with capillary electrophoresis Protein Sci. 19 2010 888 892
129. H.D. Jetani, A.K. Bhadra, N.K. Jain, and A. Roy Nucleic acid aptamers stabilize proteins against different types of stress conditions J. Pharm. Sci. 103 2014 100 106
130. H. Ishikawa, M. Shimoda, A. Yonekura, K. Mishima, K. Matsumoto, and Y. Osajima Irreversible unfolding of myoglobin in an aqueous solution by supercritical carbon dioxide J. Agric. Food Chem. 48 2000 4535 4539
131. B. Lelj-Garolla, and A.G. Mauk Self-association of a small heat shock protein J. Mol. Biol. 345 2005 631 642
132. I.M. Keznetsova, A.G. Biktashev, S.Y. Khaitlina, K.S. Vassilenko, K.K. Turoverov, and V.N. Uversky Effect of self-association on the structural organization of partially folded proteins: inactivated actin Biophys. J. 77 1999 2788 2800
133. S. Zorrilla, G. Rivas, A.U. Acuña, and M.P. Lillo Protein self-association in crowded protein solutions: a time resolved fluorescence polarization study Protein Sci. 13 2004 2960 2969
134. K. Snoussi, and B. Halle Protein self-association induced by macromolecular crowding: a quantitative analysis by magnetic relaxation dispersion Biophys. J. 88 2005 2855 2866
135. S. Yoshioka, and V.J. Stella Stability of peptide and protein pharmaceuticals Stability of Drugs and Dosage Forms 2000 Kluwer Academic/Plenum Publisher New York 191
136. A.M. Lasdun, R.R. Kurumbali, N.K. Leimgruber, and A.S. Rathore Validatibility of a capillary isoelectric focusing method for impurity quantitation J. Chromatogr. A 917 2001 147 158